A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies
NCT ID: NCT04008524
Last Updated: 2025-08-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
AVAILABLE
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
NCT03121625
Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies
NCT03881774
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
NCT06911710
Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies
NCT04007978
CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
NCT03312205
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CAR-T cells
Chimeric Antigen Receptor-T cells
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
* Patients who have relapsed after remission following CAR-T cell therapy, and are expected as judged by the investigator to benefit more from re-use of the same cell or sequential use of other CAR-T cells compared with the risk;
* The quantity of CAR-T cells produced does not meet the release criteria of production quality inspection, but is \>0.1× 106/kg CAR positive T cells, and the investigator judges that the expected benefit of cell infusion is greater than the risk;
* The disease progresses rapidly after cell collection and before infusion, and the investigator judges that the expected benefit of cell infusion is greater than the risk;
* Patients who have relapsed after autologous/heterogeneous hematopoietic stem cell transplantation (including those positive for minimal residual disease);
* Other circumstances where the investigator judges that the expected benefit of cell infusion is greater than the risk.
* Patients with appropriate bone marrow reserve: such as lymphocyte count \>0.3×109/L;
* Patients with proper heart, lung, liver, kidney and coagulation functions;
* The selected patients or their legal representatives voluntarily sign the informed consent form.
* Patients who are positive for any of HIV antibody, TP antibody, HBsAg and HCV antibody.
* Patients with a history of epilepsy or other central nervous system diseases.
* Patients with evidence of currently uncontrollable serious active infections (e.g., sepsis, bacteremia, fungemia, viremia, etc.).
* Patients with other conditions making the patients unsuitable for receiving cell therapy as judged by the investigator.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Juventas Cell Therapy Ltd.
INDUSTRY
Institute of Hematology & Blood Diseases Hospital, China
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Hematology & Blood Diseases Hospital
Tianjin, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
QT2019006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.